Unity Biotechnology, Inc. (UBX)

1,4800 +0,0100 (+0,68%) Börsenschluss: 04:00PM EDT

Unity Biotechnology, Inc.

285 East Grand Avenue
South San Francisco, CA 94080
United States
650 416 1192
https://unitybiotechnology.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 19

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Dr. Anirvan Ghosh Ph.D.	CEO & Director	1,08M	N/A	1964
Dr. Nathaniel E. David A.B., Ph.D.	Co-Founder & Executive Director	40k	N/A	1968
Ms. Lynne Marie Sullivan	CFO & Head of Corporate Development	730,82k	N/A	1967
Dr. Jan M. van Deursen	Founder	N/A	N/A	N/A
Dr. Judith Campisi Ph.D.	Founder	N/A	N/A	N/A
Mr. Daohong Zhou M.D.	Founder	N/A	N/A	N/A
Mr. Alexander Hieu Nguyen J.D.	Chief Legal Officer, Head of Operations & Corporate Secretary	N/A	N/A	1978
Dr. Przemyslaw Sapieha Ph.D.	Chief Scientist	N/A	N/A	N/A
Ms. Sharon Klier M.D., M.P.H.	Head of Ophthalmology & Chief Development Officer	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2022 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is phase II clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. It also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of age-related eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California.

Corporate Governance

Unity Biotechnology, Inc.s ISS Governance QualityScore, Stand 1. April 2024, lautet 10. Die grundlegenden Scores sind Audit: 8, Vorstand: 9, Shareholderrechte: 8, Kompensation: 10.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.